







Figure 2A




Figure 2B

MAGEC2_7 SESSTYTDKVAELVFLLIKYEAEPTAEALNIVIKDYFPVILKRAREFNELLGLALI-----
MAGEC2_8 -----KYAEPTAEALNIVIKDYFPVILKRAREFNELLGLALIEVOPDNFCVFANTVGLDEGSD-----
MAGEC2_9 -----YFPVILKRAREFNELLGLALIEVOPDNFCVFANTVGLDEGSDDETPENSLLLLILSVIFIKON-----

Figure 2C
Peptide Validation




Figure 3A




Figure 3B




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 6




Figure 7A




Figure 7B

Model 1	GGSTYLLDQWAEIPEFLIKAEQVIEE-LIVINQDVFVILKREF-ELIPLA-L
Model 2	8VEEEVIEE-LIVIKQVFWILKREF-ELIPLAIDVDFP-VFANTVLDKQD
Model 3	VFVILKREF-ELIPLAIEVDFP-VFANTVLDKQDFFELLIIITLVYFTRKQ
Model 4	EVDQDF-VFANTVLDKQDFFELLIIITLVYFTRKQAEETVNEELAVQVAFEE

Figure 7C



Figure 8A




Figure 8B




Figure 8C




Figure 9A




Figure 9B

Killing of Melanoma cell line HT144 (E:T 4:1)

